INMB
INmune Bio Inc
$
2.710
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.830
Open
2.770
VWAP
2.71
Vol
1.34M
Mkt Cap
72.05M
Low
2.615
Amount
3.63M
EV/EBITDA(TTM)
--
Total Shares
19.78M
EV
52.71M
EV/OCF(TTM)
--
P/S(TTM)
1.14K
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.
Show More
6 Analyst Rating
184.87% Upside
Wall Street analysts forecast INMB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INMB is 7.72 USD with a low forecast of 0.60 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
3 Hold
1 Sell
Hold
184.87% Upside
Current: 2.710
Low
0.60
Averages
7.72
High
21.00
184.87% Upside
Current: 2.710
Low
0.60
Averages
7.72
High
21.00
Alliance Global Partners
Buy
downgrade
$20 -> $7
2025-07-03
Reason
Alliance Global Partners
Price Target
$20 -> $7
2025-07-03
downgrade
Buy
Reason
Alliance Global Partners lowered the firm's price target on INmune Bio to $7 from $20 and keeps a Buy rating on the shares after the company reported topline Phase 2 data from the MINDful trial of XPro for Alzheimer's disease that "were not what we had hoped for." The firm adjusted its price target to account for the added uncertainly around the future development for XPro and the additional time that will be needed to find a partner and start confirmatory trials, noting that it now values XPro for Alzheimer's at $3 per share.
Maxim
Jason McCarthy
Buy
downgrade
$30 -> $8
2025-07-02
Reason
Maxim
Jason McCarthy
Price Target
$30 -> $8
2025-07-02
downgrade
Buy
Reason
Maxim analyst Jason McCarthy lowered the firm's price target on INmune Bio to $8 from $30 but keeps a Buy rating on the shares. The firm cites the failure of lead drug XPro to demonstrate clinical improvements in the company's Phase 2 Alzheimer's disease trial, but while the top-line data is disappointing, there were some promising aspects and the company continues to develop its pipeline, the analyst tells investors in a research note.
Scotiabank
Outperform -> Underperform
downgrade
$23
2025-07-01
Reason
Scotiabank
Price Target
$23
2025-07-01
downgrade
Outperform -> Underperform
Reason
Scotiabank downgraded INmune Bio to Underperform from Outperform with a price target of 60c, down from $23, based on the failure of lead drug XPro to demonstrate clinical improvements in the company's Phase 2 Alzheimer's disease trial. The firm think management's plan of securing CORDStrom FDA approval for treatment of recessive dystrophic epidermolysis bullosa has a "very low chance of success," the analyst tells investors.
BTIG
Buy -> Neutral
downgrade
$21
2025-06-30
Reason
BTIG
Price Target
$21
2025-06-30
downgrade
Buy -> Neutral
Reason
BTIG downgraded INmune Bio to Neutral from Buy and removed the firm's prior $21 price target after XPro Phase 2 data in early Alzheimer's disease, AD. The results marks another failure of anti-inflammatory approaches in the treatment of AD - despite the clear signs of inflammation in the brains of AD patients and the decades of animal work showing that CNS-inflammation is a negative regulator of neuronal and microglial function, the analyst tells investors in a research note.
Raymond James
Gary Nachman
Outperform -> Market Perform
downgrade
2025-06-30
Reason
Raymond James
Gary Nachman
Price Target
2025-06-30
downgrade
Outperform -> Market Perform
Reason
Raymond James analyst Gary Nachman downgraded INmune Bio to Market Perform from Outperform.
Raymond James
Outperform -> Market Perform
downgrade
$23
2025-06-30
Reason
Raymond James
Price Target
$23
2025-06-30
downgrade
Outperform -> Market Perform
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for INmune Bio Inc (INMB.O) is -2.04, compared to its 5-year average forward P/E of -5.28. For a more detailed relative valuation and DCF analysis to assess INmune Bio Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-5.28
Current PE
-2.04
Overvalued PE
-2.87
Undervalued PE
-7.69
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
2336.19
Current PS
0.00
Overvalued PS
7622.97
Undervalued PS
-2950.60
Financials
Annual
Quarterly
FY2025Q1
YoY :
+257.14%
50.00K
Total Revenue
FY2025Q1
YoY :
-10.09%
-9.91M
Operating Profit
FY2025Q1
YoY :
-11.66%
-9.74M
Net Income after Tax
FY2025Q1
YoY :
-29.51%
-0.43
EPS - Diluted
FY2025Q1
N/A
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
YoY :
-75.27%
-19.48K
Net Margin - %
Trading Trends
Insider
Insiders areBuying! The selling amount has increased 450.04% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
3
199.9K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areBuying! The selling amount has increased 450.04% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
3
199.9K
USD
Months
INMB News & Events
Events Timeline
2025-07-24 (ET)
2025-07-24
07:16:50
INmune Bio announces analyses from Phase 2 MINDFuL trial, endpoint not met
2025-06-30 (ET)
2025-06-30
07:33:30
INmune Bio reports findings from Phase 2 MINDFuL trial of XPro
2025-06-30
06:56:03
INmune Bio down 52% after primary endpoint of MINDFuL study not met
Sign Up For More Events
Sign Up For More Events
News
9.0
07-24NewsfilterPinnedINmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer's Association International Conference
6.5
07-04Benzinga'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday
4.0
07-01BenzingaThis Textron Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Sign Up For More News
People Also Watch
TDTH
Trident Digital Tech Holdings Ltd
1.340
USD
-0.74%
VERU
Veru Inc
0.561
USD
-6.50%
TSQ
Townsquare Media Inc
7.320
USD
+0.97%
HOFT
Hooker Furnishings Corp
11.470
USD
+2.23%
VTYX
Ventyx Biosciences Inc
3.180
USD
-0.63%
WHG
Westwood Holdings Group Inc
18.030
USD
+0.22%
SGMT
Sagimet Biosciences Inc
10.240
USD
+0.39%
OPRT
Oportun Financial Corp
6.360
USD
+0.95%
ALTO
Alto Ingredients Inc
1.180
USD
0.00%
MPAA
Motorcar Parts of America Inc
12.140
USD
+0.17%
FAQ
What is INmune Bio Inc (INMB) stock price today?
The current price of INMB is 2.71 USD — it has decreased -2.52 % in the last trading day.
What is INmune Bio Inc (INMB)'s business?
What is the price predicton of INMB Stock?
What is INmune Bio Inc (INMB)'s revenue for the last quarter?
What is INmune Bio Inc (INMB)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for INmune Bio Inc (INMB)'s fundamentals?
How many employees does INmune Bio Inc (INMB). have?